Back to Search Start Over

SOLTI-1904 ACROPOLI TRIAL: efficacy of spartalizumab monotherapy across tumor-types expressing high levels of PD1 mRNA.

Authors :
Prat, Aleix
Paz-Ares, Luis
Juan, Manel
Felip, Enriqueta
Garralda, Elena
González, Blanca
Arance, Ana
Martín-Liberal, Juan
Gavilá, Joaquín
López-González, Ana
Cejalvo, Juan Miguel
Izarzugaza, Yann
Amillano, Kepa
Corbacho, Javier García
Saura, Cristina
Racca, Fabricio
Hierro, Cinta
Sanfeliu, Esther
Gonzalez, Xavier
Canes, Jordi
Source :
Future Oncology; Nov2022, Vol. 18 Issue 34, p3791-3800, 10p
Publication Year :
2022

Abstract

Improved selection of cancer patients who are most likely to respond to immune checkpoint inhibitors remains an unmet clinical need. Recently, a positive correlation between levels of PD1 mRNA and clinical outcome in response to PD1 blockade across diverse tumor histologies has been confirmed in several datasets. ACROPOLI is a parallel cohort, non-randomized, phase II study that aims to evaluate the efficacy of the anti-PD1 immune checkpoint inhibitor spartalizumab as monotherapy in metastatic patients with solid tumors that express high levels of PD1 (cohort 1; n = 111). An additional cohort of 30 patients with tumors expressing low levels of PD1, where PD1/PD-L1 antibodies in monotherapy are standard treatment, will also be included (cohort 2). Primary end point is overall response rate in cohort 1. Clinical Trial Registration:NCT04802876 (ClinicalTrials.gov) Considering previous data, we hypothesized that anti-PD1 monotherapy is effective across multiple cancer types in patients with PD1-high mRNA expressing tumors. Given these observations, ACROPOLI is a phase II study designed to study spartalizumab in this population. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
14796694
Volume :
18
Issue :
34
Database :
Complementary Index
Journal :
Future Oncology
Publication Type :
Academic Journal
Accession number :
161226174
Full Text :
https://doi.org/10.2217/fon-2022-0660